Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW0ZV1
|
|||
| Drug Name |
Afimetoran
|
|||
| Synonyms |
Afimetoran; 2171019-55-7; Afimetoran [USAN]; LXP7MZL0VF; BMS-986256; UNII-LXP7MZL0VF; WHO 11516; BMS 986256; 2-(4-(2-(7,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)acetamide; 1-Piperidineacetamide, 4-(2-(7,8-dimethyl(1,2,4)triazolo(1,5-a)pyridin-6-yl)-3- (1-methylethyl)-1H-indol-5-yl)-; 2-(4-(2-(7,8-dimethyl(1,2,4)triazolo(1,5-a)pyridin-6-yl)-3-(propan-2-yl)-1H-indol-5-yl)piperidin-1-yl)acetamide; AFIMETORAN [INN]; CHEMBL4650329; SCHEMBL19761011; BDBM273241; EX-A6745; US10071079, Example 15; AKOS040757385; MS-28017; HY-139567; CS-0213544; 1-PIPERIDINEACETAMIDE, 4-(2-(7,8-DIMETHYL(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-3-(1-METHYLETHYL)-1H-INDOL-5-YL)-; 2-(4-(2-(7,8-DIMETHYL(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-3-(PROPAN-2-YL)-1H-INDOL- 5-YL)PIPERIDIN-1-YL)ACETAMIDE; 2-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl) piperidin-1-yl)acetamide; 2-[4-[2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-propan-2-yl-1H-indol-5-yl]piperidin-1-yl]acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H32N6O
|
|||
| Canonical SMILES |
CC1=C(C2=NC=NN2C=C1C3=C(C4=C(N3)C=CC(=C4)C5CCN(CC5)CC(=O)N)C(C)C)C
|
|||
| InChI |
InChI=1S/C26H32N6O/c1-15(2)24-20-11-19(18-7-9-31(10-8-18)13-23(27)33)5-6-22(20)30-25(24)21-12-32-26(28-14-29-32)17(4)16(21)3/h5-6,11-12,14-15,18,30H,7-10,13H2,1-4H3,(H2,27,33)
|
|||
| InChIKey |
SNFVHLQYHFQOEP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Toll-like receptor 7 (TLR7) | Target Info | Inhibitor | [2] |
| Toll-like receptor 8 (TLR8) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Toll-like receptor signaling pathway | |||
| Measles | ||||
| Influenza A | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Toll receptor signaling pathway | |||
| Reactome | Trafficking and processing of endosomal TLR | |||
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | ||||
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Toll-Like Receptors Cascades | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| Trafficking and processing of endosomal TLR | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04895696) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Systemic Lupus Erythematosus. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.